Study of Treatment for HPV16+ ASC-US or LSIL (PVX-6)

The University of Alabama at Birmingham

Status and phase: Enrolling; Phase 1

Conditions: LSIL; ASC-US

Treatments: Biological: TA-CIN; Biological: pNGVL4aCRTE6E7L2

Study type: Interventional

Funder types: Other

Identifiers

NCT03913117

000540585 (Other Identifier)

BB IND 18340

Details and patient eligibility

About

Phase I clinical trial to assess safety of pNGVL4aCRTE6E7L2 DNA and TA-CIN protein vaccinations, and to seek the appropriate dose of the pNGVL4aCRTE6E7L2 DNA vaccine

Full description

Primary Objectives

1. To determine the safety and feasibility of intra-muscular administration of pNGVL4aCRTE6E7L2 DNA vaccine in patients with persistent HPV16+ ASC-US/LSIL.
2. To determine the appropriate intra-muscular injection dose of pNGVL4aCRTE6E7L2 DNA vaccine as determined by toxicity and immunogenicity for a subsequent phase II clinical trial.
3. To determine the safety and feasibility of intra-muscular administration of pNGVL4aCRTE6E7L2 DNA vaccine prime, TA-CIN protein vaccine boost in patients with persistent HPV16+ ASC-US/LSIL.

Enrollment: 30 estimated patients

Sex: Female

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with persistent (>6 month period) ASC-US/LSIL determined by cervical cytology at study entry (ThinPrep with imaging)

2. Patients whose cytologic samples are persistent (>6 month period) HPV16+ by Roche Cobas 4800, Roche Linear Array HPV Genotyping test or other FDA-approved HPV genotyping test at study entry. Co-infections with HPV types other than HPV16 are permissible for study entry.

3. Age ≥ 19 years

4. Baseline Eastern Cooperative Oncology Group

5. Patients must have adequate organ function at the time of enrollment as defined by the following parameters:

   • White blood cell count > 3,000
   • Absolute lymphocyte number > 500
   • Absolute neutrophil count > 1,000
   • Platelets > 90,000
   • Hemoglobulin > 9
   • Total bilirubin <3 X the institutional limit of normal
   • AST(SGOT)/ALT(SGPT) <3 X the institutional limit of normal
   • Creatinine < 2.5X the institutional limit of normal

6. Women of child-bearing potential must agree to use two forms of contraception (hormonal and barrier) prior to study entry and for 3 months after study completion.

7. Ability to understand and the willingness to sign a written informed consent document.

8. Subject is able to adhere to the study visit schedule and other protocol requirements.

Exclusion criteria

1. Patients with ASC-US/LSIL determined by cervical cytology at study entry that are HPV16 negative.
2. Histologic evidence of CIN2+
3. Patients with a diagnosis of immunosuppression or prolonged, active use of immunosuppressive medications such as steroids.
4. Prior vaccination with any HPV antigen (prophylactic or therapeutic).
5. Patients who are receiving any other investigational agents within 28 days prior to the first dose.
6. Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
7. Patients with a history of autoimmune disease such as multiple sclerosis, exclusive of a history of thyroiditis, psoriasis, Sjrogen's, or inflammatory bowel disease.
8. Patients with a history of allergic reactions attributed to compounds used in agent preparation.
9. Patients who are pregnant or breast feeding.
10. Patient with active or chronic infection of HIV, HCV, or HBV.
11. Patients who have had a prior LEEP or cervical conization procedure.
12. History of prior malignancy permitted if patient has been disease free for ≥ 5 years; however individuals with completely resected basal cell or squamous cell carcinoma of the skin within this interval may be enrolled.
13. Inability to understand or unwillingness to sign an informed consent document.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

30 participants in 4 patient groups

pNGVL4aCRTE6E7L2 0.3mg dose

Experimental group

Description:

Low dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.

Treatment:

Biological: pNGVL4aCRTE6E7L2

pNGVL4aCRTE6E7L2 1 mg dose

Experimental group

Description:

Intermediate dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.

Treatment:

Biological: pNGVL4aCRTE6E7L2

pNGVL4aCRTE6E7L2 3 mg dose

Experimental group

Description:

High dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0, 4 and 8.

Treatment:

Biological: pNGVL4aCRTE6E7L2

PVX-6

Experimental group

Description:

Selected dose of pNGVL4aCRTE6E7L2 plasmid DNA is administered by intramuscular injection at weeks 0 and 4, and the TA-CIN protein is administered by intramuscular injection at week 8.

Treatment:

Biological: pNGVL4aCRTE6E7L2

Biological: TA-CIN